. Author manuscript; available in PMC: 2008 Feb 15.

Published in final edited form as: Clin Pharmacol Ther. 2007 May 9;83(1):52–60. doi: 10.1038/sj.clpt.6100221

Table 4.

G-765C polymorphism in PTGS2, aspirin utilization, and risk of incident CHD events in Caucasians

	Non-cases G/C+C/C	CHD cases G/C+C/C	P-value	HRR^aG/C+C/C versus G/G	95% CI	P-value
All patients	182 (29.0%)	230 (29.6%)	0.808	1.08	0.83–1.42	0.567
Baseline (n=1,376)^b
No aspirin	121 (27.9%)	170 (31.7%)	0.232	1.36	0.97–1.90	0.075
Aspirin	60 (31.5%)	59 (25.0%)	0.165	0.60	0.36–1.02	0.058
Interaction^c				0.57	0.31–1.05	0.072
Baseline and visit 2 (n=859)^d
No aspirin	90 (29.5%)	98 (30.7%)	0.745	1.40	0.93–2.09	0.107
Aspirin	32 (30.4%)	33 (23.9%)	0.295	0.55	0.26–1.18	0.128
Interaction^b				0.43	0.19–0.99	0.047

CI, confidence interval; HRR, hazard rate ratio.

Adjusted for age, gender, study center, current smoker, diabetes, hypertension, high-density lipoprotein cholesterol, total cholesterol, and body mass index.

Aspirin utilization assessed (yes/no) at the baseline visit only. No aspirin=no. Aspirin=yes. Excluded=none.

Multiplicative G-765C by aspirin utilization interaction term.

Aspirin utilization assessed (yes/no) at the baseline and first follow-up visit. No aspirin=no at both visits. Aspirin=yes at both visits. Excluded=yes at only one visit.